Implications and consequences of enzyme induction on preclinical and clinical drug development

Xenobiotica

Volumn 31, Issue 8-9, 2001, Pages 539-556

  Worboys, P D ^a   Carlile, D J ^a  

^a UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450; DEXAMETHASONE; DRUG; ENZYME INDUCING AGENT; FELBAMATE; LANSOPRAZOLE; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; RIFABUTIN; RIFAMPICIN; TROGLITAZONE; WARFARIN;

ARTICLE; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECT; DRUG METABOLISM; DRUG SAFETY; ENZYME INDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CULTURE; PREDICTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TOXICITY TESTING;

ANIMALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ENZYME INDUCTION; HEPATOCYTES; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; TOXICOLOGY;

EID: 0034831129     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250110054623     Document Type: Article

References (69)

1. The relationship among microsomal enzyme induction, liver weight and histological change in rat toxicology studies
2. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole
3. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbemazepine or phenytoin
4. The effects of rifampicin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive
5. Induction of cytochrome P-450 in cultured rat hepatocytes. The heterogeneous localization of specific isoenzymes using immunocytochemistry
6. Trans-species gene transfer for analysis of glucocorticoid-inducible transcriptional activation of transiently expressed human CYP3A4 and rabbit CYP3A6 in primary cultures of adult rat and rabbit hepatocytes
7. Induction of drug-metabolizing enzymes by xenobiotics
8. Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction
9. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?
10. High throughput screening for inhibition of cytochrome P450 metabolism
11. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture
12. Quantification of CYP2B7, CYP4B1, and CYPOR messenger RNAs in normal human lung and lung tumors
13. Effect of model inducers on cytochrome P450 activities of human hepatocytes in primary culture
14. Quantitative differences in phase I and II metabolism between rat precision-cut liver slices and isolated hepatocytes
15. Improved reliability of the rapid microtitre plate assay using recombinant enzyme in predicting CYP2D6 inhibition in human liver microsomes
16. Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation
17. Long-term expression of differentiated functions in hepatocytes cultured in three-dimensional collagen matrix
18. Analysis of human cytochrome P450 catalytic activities and expression
19. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily
20. The mechanism of the warfarin - Rifampin drug interaction in humans
21. Prediction of hepatic clearance from microsomes, hepatocytes and liver slices
22. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model
23. Effects of lansoprazole on pharmacokinetics and metabolism of theophylline
24. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: Application to 10 extensively metabolized drugs
25. Strategies for restoration and maintenance of normal hepatic structure and function in long-term cultures of rat hepatocytes
26. Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: Consensus of an international expert panel
27. Preclinical evaluation of drug-drug interaction potential: Present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction
28. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: Evaluation of rifampin, rifapentine and rifabutin
29. Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent
30. A pharmacokinetic interaction between carbemazepine and olanzapine: Observations on possible mechanism
31. Identification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldithiocarbamate methyl ester: Role of P-450 enzymes in disulfiram bioactivation
32. Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: A 10-year follow-up
33. Detection of cytochrome P450 and other drug-metabolizing enzyme mRNAs in peripheral blood mononuclear cells using DNA arrays
34. Application of rat hepatocyte culture to predict in vivo metabolic auto-induction: Studies with DFP, a cyclooxygenase-2 inhibitor
35. A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro
36. Enzyme induction in the cytochrome P-450 system
37. Alteration of transcription factor mRNAs during the isolation and culture of rat hepatocytes suggests the activation of a proliferative mode underlies their de-differentiation
38. Altered expression of cytochrome P-450 mRNAs, and potentially of other transcripts encoding key hepatic functions, are triggered during the isolation of rat hepatocytes
39. The maintenance of cytochrome P-450 in rat hepatocyte culture: Some applications of liver cell cultures to the study of drug metabolism, toxicity and the induction of the P-450 system
40. Use of a novel real-time quantitative reverse transcription-polymerase chain reaction method to study the effects of cytokines on cytochrome P450 mRNA expression in mouse liver
41. Hepatic clearance of drugs. I. Theoretical considerations of a 'well stirred' and a 'parallel tube' model: Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance
42. Relevance of induction of human drug-metabolizing enzymes: Pharmacological and toxicological implications
43. Antiepileptic drugs. A review of clinically significant drug interactions
44. Human hepatocytes in primary culture predict lack of cytochrome P-450 3A4 induction by elitriptan in vivo
45. Use of precision-cut rat liver slices for studies of xenobiotic metabolism and toxicity: Comparison of the Krumdieck and Brendel tissue slicers
46. Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations
47. Rifampin and warfarin: A drug interaction
48. Piperonyl butoxide and acenaphthylene induce cytochrome P450 1A2 and 1B1 mRNA in aromatic hydrocarbon-responsive receptor knock-out mouse liver
49. Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes
50. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver
51. Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey
52. Induction and drug development
53. Influence of phenobarbital treatment on cimetidine kinetics
54. Virtual screening of intestinal drug permeability
55. Use of human hepatocytes to study P450 gene induction
56. High throughput ribonuclease protection assay for the determination of CYP3A mRNA induction in cultured rat hepatocytes
57. Rapid determination of rat hepatocyte mRNA induction potential using oligonucleotide probes for CYP1A1, 1A2, 3A and 4A1
58. Pharmacokinetic and pharmacodynamic implications of pharmacogenetics
59. The application of DNA microarrays in gene expression analysis
60. Hepatocyte isolation stimulates formation of interferon stimulatory response element DNA-protein complexes
61. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: Ratios of accessory proteins as sources of discrepancies between the approaches
62. The effect of dexamethasone on the pharmacokinetics of triazolam
63. Inhibitory anti-CYP3A4 peptide antibody: Mapping of inhibitory epitope and specificity toward other CYP3A isoforms
64. Kinetics of drug metabolism in rat liver slices. III. Relationship between metabolic clearance and slice uptake rate
65. Comparison of cytochrome P450 isoenzyme profiles in rat liver and hepatocyte cultures. The effects of model inducers on apoproteins and biotransformation activities
66. Induction of rat hepatic glucocorticoid-inducible cytochrome P450 3A by metyrapone
67. Humanized xenobiotic response in mice expressing nuclear receptor SXR
68. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinate) absorption in man - Fact or myth
69. Biomedical discovery with DNA arrays